Cardiometabolic Health Congress (CMHC) 2026 will take place from October 15 to 17, 2026, at Hilton Boston Park Plaza in Boston, Massachusetts. The 21st annual congress brings together physicians, specialists, allied healthcare professionals, researchers and industry organisations focused on cardiovascular, renal and metabolic disease. Its clinical programme connects cardiology, endocrinology, nephrology and preventive medicine, reflecting the increasingly integrated approach to conditions such as diabetes, obesity, hypertension, chronic kidney disease, dyslipidemia and atherosclerotic cardiovascular disease.
The 2026 agenda is organised across major clinical tracks including CardioRenal and Hypertension, Obesity and Lifestyle, Diabetes, and Dyslipidemia, Atherosclerosis and Thrombosis. Sessions examine topics such as the cardio-kidney-metabolic axis, resistant hypertension, diet quality, sleep and cardiometabolic risk, digital diabetes management, continuous glucose monitoring and new approaches to cardiovascular prevention. Imaging, coronary calcium scoring, CTA and artificial intelligence are also addressed as clinicians evaluate emerging tools for risk assessment and personalised patient management.
CMHC combines accredited medical education with an industry exhibition featuring pharmaceutical companies, medical-device suppliers, diagnostic providers, telehealth businesses, digital therapeutics, EHR and EMR companies and other healthcare technology organisations. Interactive workshops, case discussions and expert-led sessions are designed to translate current research into practical clinical strategies. A dedicated Women’s Cardiometabolic Health and Wellness Masterclass takes place on October 14 as a pre-conference programme, examining sex-specific risk factors, prevention and treatment across cardiorenal and metabolic health.
